Showing 1 - 20 results of 483 for search '"Fidelio"', query time: 1.39s Refine Results
  1. 1
    Book
  2. 2
    by Sánchez, Juan
    Published 1985
    Subjects: “…Ponce, Fidelio, 1895-1949.…”
    Book
  3. 3
  4. 4
  5. 5
  6. 6
    “…METHODS: Nonlinear mixed-effects population pharmacokinetic models were used to analyze the pharmacokinetics in FIDELIO-DKD, sparsely sampled in all subjects receiving finerenone. …”
    Get full text
    Get full text
    Get full text
    Online Article Text
  7. 7
    “…BACKGROUND: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in FIDELIO-DKD, where 5734 patients were randomized 1:1 to receive either finerenone or placebo, with a median follow-up of 2.6 years. …”
    Get full text
    Get full text
    Get full text
    Online Article Text
  8. 8
    “…We performed dose–exposure–response analyses to determine the effects of finerenone on these surrogates in the presence and absence of sodium glucose co-transporter-2 inhibitors (SGLT2is) using individual patient data from the FIDELIO-DKD study. METHODS: Non-linear mixed-effects population pharmacokinetic/pharmacodynamic models were used to quantify disease progression in terms of UACR and eGFR during standard of care and pharmacodynamic effects of finerenone in the presence and absence of SGLT2i use. …”
    Get full text
    Get full text
    Get full text
    Online Article Text
  9. 9
  10. 10
  11. 11
    “…AIMS: This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF). …”
    Get full text
    Get full text
    Get full text
    Online Article Text
  12. 12
  13. 13
    “…AIMS: Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO‐DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on the treatment effect of finerenone. …”
    Get full text
    Get full text
    Get full text
    Online Article Text
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
Search Tools: RSS Feed